ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullishWuXi XDC Cayman
16 Nov 2023 15:32

WuXi XDC IPO: Trading Debut

The market sentiment on the sector has modestly weakened. However, the IPO price is attractive, with our DCF valuation of HK$22.89 per share, 11.1%...

Logo
409 Views
Share
bullishWuXi XDC Cayman
16 Nov 2023 08:09

WuXi XDC Cayman IPO Trading - Strong Subscription Rates Heading into Listing

WuXi XDC Cayman (1877628D HK) raised US$470m in its Hong Kong IPO. In our previous notes, we looked at the company’s past performance and...

Logo
456 Views
Share
bullishTencent
13 Nov 2023 08:08

HK Connect SOUTHBOUND (To 10 Nov 23); High-Div SOEs AGAIN See Outflows, Tencent and ETFs Big Buys

In last week's SOUTHBOUND flows, high dividend SOEs such as China Mobile and CNOOC again saw net selling while Tencent and three major listed ETFs...

Logo
363 Views
Share
12 Nov 2023 10:05

HK Short Interest Weekly: HSBC, Haidilao, China Mobile

We analyzed the latest HK SFC report for aggregate short position as of Nov 3rd and highlight short interest changes in HSBC, Haidilao, China Mobile.

Logo
372 Views
Share
bullishWuXi XDC Cayman
08 Nov 2023 10:05

WuXi XDC IPO: Valuation Insights

Blue-chip cornerstones will purchase US$300 million of the offer. Our base-case DCF valuation is HK$22.84 per share, 12.8% above the midpoint of...

Logo
568 Views
Share
x